20 articles
A Phase 1/2 trial tests whether nicotinamide riboside can restore NAD+ balance and improve heart function in systolic HF patients.
Review reveals how NAD+ precursors like NMN could restore heart function by fixing cellular energy production and reducing oxidative damage.
Deleting GTPBP3 in endothelial cells blocks angiogenesis via mtROS overload — and a mitochondria-targeted antioxidant reverses the damage.
New research reveals how a key RNA processing protein helps immune cells mature properly to fight artery plaque buildup.
Scientists identify GSDME as a master switch driving abdominal aortic aneurysms through vascular aging, opening new treatment paths.
Small trial explores how amiloride improves oxygen delivery to heart muscle by enhancing potassium transport in red blood cells.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
A longevity-linked protein blocks two key mechanisms of doxorubicin heart damage, offering a potential cardioprotective strategy for cancer patients.
High-dose nicotinamide riboside increased atherosclerotic plaques and inflammation in mice, challenging NAD+ supplement safety.
Scientists identify GPRASP1 as a key guardian of pulmonary vascular health, opening a potential drug target for PH-HFpEF.
A 2025 review examines how methylene blue's nitric oxide inhibition can restore vascular tone in septic and vasoplegic shock patients.
Sotatercept emerges as potential treatment for combined pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction.
A sirtuin enzyme prevents heart scarring by keeping cardiac fibroblasts from switching to a pro-fibrotic metabolic state.
A new molecular target — the E3 ubiquitin ligase Hrd1 — may prevent heart damage after blood flow is restored following a heart attack.
Clinical trial shows memantine reduces premature atrial contractions by 47% and prevents atrial fibrillation in heart patients.
New research reveals how PINK1-mediated mitophagy protects against heart failure by preventing inflammatory DNA release from damaged mitochondria.
New research reveals NAD metabolism governs how blood vessels stabilize after growth, with implications for cancer and eye disease.
A phase 2 trial of the microRNA-132 inhibitor CDR132L showed safety but no significant improvement in cardiac remodeling after heart attack.
Breakthrough treatment works through multiple mechanisms beyond the lungs, enhancing oxygen delivery and muscle function.
Isolinderalactone from Lindera aggregata root reduces atherosclerotic plaques by targeting key inflammatory pathways in immune cells.
